ADA Scientific Sessions Recap—Day #4: Simi Ahmed, Ph.D.
The American Diabetes Association’s Scientific Sessions is almost coming to a close! Here is Simi Ahmed, Ph.D., head of the immune therapy program at Breakthrough T1D, who highlights some of the important immune-based therapies and what they mean for the type 1 diabetes community:
First Human Study to Significantly Delay—by Two Years!—Type 1 Diabetes Onset
This is big. No, wait, this is ENORMOUSLY HUGE. Published today in the New England Journal of Medicine, an immune therapy demonstrated a significant delay in the time to onset of type 1 diabetes (T1D) in high-risk relatives of people with the disease. A significant delay meaning 2+ years! This is the first ever study […]
Your Cancer is Gone; Type 1 Diabetes is Here
Immune therapy has transformed cancer care. In some cases, cancer is effectively cured in people with stage 4 disease. But it has a catch: In about one percent of people treated with immune therapy, their immune system goes haywire, and it attacks the beta cells in the pancreas, leaving them with type 1 diabetes (T1D) […]
Closer to Cure: Renewed Funding for Type 1 Diabetes UK Immunotherapy Consortium (T1D UK)
More than 400,000 people in the United Kingdom and 1.25 million Americans have type 1 diabetes (T1D), a disease for which there is no cure yet. Type 1 Diabetes UK Immunotherapy Consortium (T1D UK), a network of British scientists, backed by Diabetes UK and Breakthrough T1D, are conducting clinical trials to find new treatments that […]
JDRF-Backed Start-Up Company to Accelerate Work Through Pfizer
AnTolRx, Inc., a private biotechnology company, has agreed to license its immune tolerance therapy for type 1 diabetes (T1D) to Pfizer with the aim of advancing the research and accelerating its potential for commercialization. The research is part of a larger portfolio of work done by AnTolRx, a Cambridge, Massachusetts-based research and development biotechnology company. […]
